Gene Insertion - Pluripotent Stem Cells 2012-2017

The National Institutes of Health (NIH) National Heart, Lung and Blood Institute established this Master IDIQ on August 30, 2012 to procure stem cell lines and develop protocols and standard operating procedures for deriving, culturing, and differentiating pluripotent stem cells in support of the NIH intramural research program. The vehicle is closed — ordering ceased on September 16, 2017, more than eight years ago, and all four task orders placed under it have been completed.

The vehicle awarded four delivery orders between September 18 and September 24, 2012, all on firm fixed price terms. Lonza Walkersville, Inc. received two orders totaling $1.1 million in combined potential value, with one extending through September 2017; Xcell Science Incorporated received one order valued at $1 million; and Cellectis Bioresearch Inc. received one order valued at $750. Three of the four orders carried no set-aside designation; one was small-business set-aside. The combined task-order potential value across the vehicle was $2.2 million, and $2.2 million (100 percent) was obligated.

Most orders funded the NIH National Heart, Lung and Blood Institute, which placed two orders with a combined potential value of $1.7 million. The NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases and the NIH Office of the Director each placed one order. All task orders specified firm fixed price pricing and ultimate completion dates ranging from February 2014 to September 2017.

This vehicle represents a closed, time-limited program for a specific NIH intramural research initiative. Pursuit is not feasible.

The NIH in Bethesda, National Heart, Lung and Blood Institute (NHLBI), for the National Institutes of Health Center for Regenerative Medicine (NIH-CRM) is a resource for the National Institutes of Health intramural Research Program (NIH IRP) in the area of stem cell technology. One main goal of the NIH-CRM is to provide the NIH IRP with support in order to move research in the area of stem cell technology forward. This is a Master IDIQ for procurement of stem cell lines and developing protocols and standard operating procedures in order to derive, culture, and differentiate stem cells.